Alector (ALEC) Preferred Stock Liabilities (2018)
Alector (ALEC) posted quarterly Preferred Stock Liabilities of $210.5 million for Q4 2018, little changed quarter-over-quarter from $210.2 million in Q3 2018.
Alector (ALEC) Preferred Stock Liabilities (2018) Analysis & Trends
Alector (ALEC) has reported Preferred Stock Liabilities for 1 consecutive years, with $210.5 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Preferred Stock Liabilities changed N/A year-over-year to $210.5 million; the TTM figure through Dec 2018 stood at $210.5 million (changed N/A YoY), while the FY2018 annual figure was $210.5 million, up 171.69% from the prior year.
- Preferred Stock Liabilities steadied at $210.5 million in Q4 2018 per ALEC's latest filing, from $210.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $210.5 million in Q4 2018 and bottomed at $77.5 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 210.52 Mn |
| Sep 30, 2018 | 210.17 Mn |
| Jun 30, 2018 | 147.57 Mn |
| Mar 31, 2018 | 77.49 Mn |